NASDAQ$AYTU
Aytu BioScience Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Aytu BioPharma reported record revenues, prescriptions, and adjusted EBITDA for Q4 2023.
Aytu BioPharma reported a strong Q4 2023 with record revenues of $30.7 million, a 12% increase year-over-year, and a positive Adjusted EBITDA of $7.7 million. The company's Rx segment drove growth with record prescriptions and revenues, while the Consumer Health segment is being de-emphasized to improve profitability. Aytu is focusing on its core Rx segment and expects to achieve net income going forward.
- Total net revenue reached $30.7 million, a 12% increase year-over-year.
- Rx segment net revenue was $23.3 million, a 24% increase year-over-year.
- Total quarterly promoted Rx product prescriptions increased 32% year-over-year to 155,562.
- Adjusted EBITDA was a positive $7.7 million, compared to a negative $3.9 million in the year-ago quarter.
Headline financials
Revenue & EPS history
Aytu BioScience · Revenue · Quarterly
$30.7M
Revenue by segment
Aytu BioScience · $210K total across 1 segment · Q4 2023
- Other$210K-42.6%100.0%
Forward guidance
Aytu BioPharma expects continued growth of the Rx Segment in fiscal 2024 and believes it is well-positioned to cover operational expenses and drive shareholder value.
Tailwinds
- Continued growth of the Rx Segment in fiscal 2024
- Well-positioned to cover operational expenses
- Drive shareholder value
- Manufacturing transfer of Adzenys XR-ODT and Cotempla XR-ODT can materially add to ADHD gross profit margins.
- Company expects a six-month review of the PAS submission, which would enable FDA approval by late calendar 2023 or early calendar 2024
Headwinds
- Winding down the Consumer Health segment
- Suspension of all pipeline development programs
- Dependence on Rx Segment growth
- Reliance on third-party manufacturers
- Potential risks associated with gaining market acceptance of products
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-1.0%
Avg return
Earnings day
-4.9%
Avg return
5 days after
-7.0%
Avg return
30 days after
19%
12 / 64 earnings
Positive
+91.7%
Q3 2025
Best reaction
-31.0%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -0.4% | -9.7% | -4.9% | |
| Q2 2026 | -3.3% | -11.8% | -4.4% | |
| Q1 2026 | -13.1% | -2.9% | +11.7% | |
| Q4 2025 | -20.1% | -31.9% | -9.6% | |
| Q3 2025 | +91.7% | +50.4% | +44.4% | |
| Q2 2025 | -0.7% | +0.7% | -13.7% | |
| Q1 2025 | -10.9% | -8.0% | -17.2% | |
| Q4 2024 | -2.9% | -3.3% | -11.1% | |
| Q3 2024 | -10.8% | -7.2% | -14.2% | |
| Q2 2024 | +4.3% | +6.0% | -4.0% | |
| Q1 2024 | -14.2% | -14.2% | +6.7% | |
| Q4 2023 | +61.8% | +76.4% | +60.6% | |
| Q3 2023 | -12.8% | -16.6% | -24.2% | |
| Q2 2023 | -5.1% | -9.9% | -29.8% | |
| Q1 2023 | +5.3% | +21.1% | +10.5% | |
| Q4 2022 | +0.0% | +0.0% | -10.5% | |
| Q3 2022 | +5.8% | +7.7% | -5.8% | |
| Q2 2022 | +5.6% | +4.8% | -13.5% | |
| Q1 2022 | -10.5% | -18.2% | -36.0% | |
| Q4 2021 | -3.7% | -0.7% | -19.9% | |
| Q3 2021 | +0.7% | +5.0% | -5.9% | |
| Q2 2021 | -5.3% | -9.0% | -5.1% | |
| Q1 2021 | -4.9% | -8.8% | -38.4% | |
| Q4 2020 | -14.1% | -16.3% | -23.0% | |
| Q3 2020 | -7.7% | -13.0% | -13.0% | |
| Q2 2020 | +2.6% | +2.6% | +49.4% | |
| Q1 2020 | -21.7% | -28.3% | -14.2% | |
| Q4 2019 | -10.9% | -16.7% | -18.8% | |
| Q3 2019 | -6.7% | -14.8% | -21.1% | |
| Q2 2019 | -22.0% | -21.2% | +6.8% | |
| Q1 2019 | -22.0% | -21.2% | +6.8% | |
| Q4 2018 | -2.8% | -13.0% | -10.2% | |
| Q3 2018 | +24.2% | +12.1% | +21.2% | |
| Q2 2018 | -31.0% | -54.5% | -86.6% | |
| Q1 2018 | -14.8% | -22.6% | -29.0% | |
| Q4 2017 | -3.0% | +3.8% | +7.8% | |
| Q3 2017 | -4.0% | -9.3% | -6.7% | |
| Q2 2017 | -4.9% | -9.8% | -16.7% | |
| Q1 2017 | +11.6% | +5.4% | +16.1% | |
| Q4 2016 | +5.3% | +2.7% | -13.1% | |
| Q3 2016 | -3.1% | — | — | |
| Q2 2016 | +7.7% | — | — | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.0% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — | |
| Q4 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro